How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

British Medical Journal

Volumn 331, Issue 7520, 2005, Pages 836-838

  Freemantle, Nick ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PIOGLITAZONE; PLACEBO;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG APPROVAL; DRUG SAFETY; HEART INFARCTION; HUMAN; LEG REVASCULARIZATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 26644439014     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.331.7520.836     Document Type: Short Survey

References (4)

1. Official PROactive results website www.proactive-results.coin/index.htm (accessed 15 Sep 2005).
2. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BWJ 2001;322:989-91.
3. Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Controlled Clin Trials 1999;20:16-39.
4. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.